Form 4: Repligen Officer Awarded RSUs and Stock Options

Repligen's Chief Accounting Officer, Violetta Hughes, received awards of 4,142 restricted stock units and 3,914 stock options.

Summary

• Violetta Hughes, Chief Accounting Officer of Repligen Corporation (RGEN), was granted 4,142 restricted stock units (RSUs) and 3,914 stock options.
• Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock.
• The RSUs will vest in equal annual installments over a five-year period, commencing on the first anniversary of the grant date.
• The stock options have an exercise price of $120.69 per share and an expiration date of September 2, 2035.
• The stock options also vest in equal annual installments over a five-year period, with each vesting date occurring on the anniversary of the grant date.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation, which is generally positive for executive retention and alignment with shareholder interests, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The awards represent a significant incentive for the Chief Accounting Officer, aligning her interests with long-term shareholder value.
• The vesting schedule over five years encourages long-term retention and performance from a key executive.

Future Outlook

The restricted stock units and stock options are subject to a five-year vesting schedule, with annual installments beginning on the first anniversary of the grant date, indicating a long-term incentive structure for the executive.

Industry Context

Executive compensation, particularly through equity awards like RSUs and stock options, is a standard practice across various industries, including biotechnology and life sciences, to attract, retain, and incentivize key talent. These awards typically align executive interests with shareholder value creation over the long term.

Comparison to Industry Standards

• The use of restricted stock units and stock options as a component of executive compensation is a common practice among publicly traded companies, including those in the biotechnology sector, such as Thermo Fisher Scientific, Danaher Corporation, and Sartorius AG, which frequently utilize similar equity-based incentives.
• A five-year vesting schedule for equity awards is within the typical range for long-term incentive plans, often seen in companies like Bio-Rad Laboratories or Agilent Technologies, designed to promote executive retention and sustained performance.

Related Party Transactions

• The transaction involves the grant of equity awards (restricted stock units and stock options) to Violetta Hughes, the Chief Accounting Officer of Repligen Corporation, which is a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: The awards align the Chief Accounting Officer's interests with long-term shareholder value creation, potentially leading to improved performance and retention of a key executive.
• Employees: May signal a stable and rewarding environment for key personnel, potentially boosting morale and retention.

Next Steps

• The restricted stock units and stock options will begin vesting in equal annual installments over a five-year period, starting on the first anniversary of the September 2, 2025 grant date.

Key Dates

Keywords

Repligen, RGEN, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Award